Source: Silo Wellness Facebook
  • Common shares of Silo Wellness (SILO) are now eligible for electronic clearing and settlement through the DTC
  • DTC eligibility accelerates the settlement process for investors and brokers, enabling Silo’s stock to be traded over a wider selection of brokerage firms
  • Silo Wellness is a holding company focused on functional mushroom and psychedelic opportunities
  • Silo Wellness Inc. (SILO) opened trading at C$0.055 per share

Common shares of Silo Wellness (SILO) are now eligible for electronic clearing and settlement through the Depository Trust Company (DTC).

This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a wider selection of brokerage firms.

Douglas K. Gordon, Chief Executive Officer of Silo Wellness commented on the news.

“DTC eligibility is an important milestone in putting our story of ‘psychedelic healing now’ through Marley One mushroom products and wellness retreats in front of a broader audience of potential shareholders who share in our vision. This process speeds up the execution of trades and simplifies the transferring of shares between brokerages in the United States. DTC eligibility is also important for increasing our connections with the U.S. capital markets and increasing the liquidity of our stock.”

Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities that benefit from a unified ecosystem and exceptional leadership.

Silo Wellness Inc. (SILO) opened trading at C$0.055 per share.

More From The Market Online

Psychedelic stock begins take-home LSD microdosing clinical trial

MindBio Therapeutics (CSE:MBIO) secures approvals for MB22001 – a form of LSD – microdosing use by patients in a controlled clinical trial.

Red Light Holland begins experimental research on psilocybin truffles

Red Light Holland has revealed that it has officially begun an experimental research project on its psilocybin truffles.
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.